Correction to: Regulation of dopaminergic function: an [18F]-DOPA PET apomorphine challenge study in humans. (Translational Psychiatry, (2017), 7, 2, (e1027), 10.1038/tp.2016.270);Regulation of dopaminergic function: An [18F]-DOPA PET apomorphine challenge study in humans

Translational Psychiatry

Volumn 7, Issue 2, 2017, Pages

  Jauhar, S ^a   Veronese, M ^a   Rogdaki, M ^b   Bloomfield, M ^b   Natesan, S ^a   Turkheimer, F ^a   Kapur, S ^a   Howes, O D ^a,b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; APOMORPHINE; AUTORECEPTOR; DOPAMINE; PLACEBO; DOPA; DOPAMINE RECEPTOR STIMULATING AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; AUTOREGULATION; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; HUMAN; MALE; NORMAL HUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; SCHIZOPHRENIA; STIMULATION; ANALOGS AND DERIVATIVES; BRAIN; DIAGNOSTIC IMAGING; DRUG EFFECTS; METABOLISM; YOUNG ADULT;

ADULT; APOMORPHINE; BRAIN; DIHYDROXYPHENYLALANINE; DOPAMINE; DOPAMINE AGONISTS; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; YOUNG ADULT;

EID: 85011891323     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/s41398-018-0187-6     Document Type: Erratum

References (75)

1. Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957; 180: 1200-1200.
2. Yokel RA, Wise RA. Increased lever pressing for amphetamine after pimozide in rats: implications for a dopamine theory of reward. Science 1975; 187: 547-549.
3. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Rev 1998; 28: 309-369.
4. Mehta SH, Morgan JC, Sethi KD. Sleep disorders associated with Parkinson's disease: role of dopamine, epidemiology, and clinical scales of assessment. CNS Spectr 2008; 13: 6-11.
5. Barbeau A. The pathogenesis of Parkinson's disease: a new hypothesis. Can Med Assoc J 1962; 87: 802.
6. Siessmeier T, Kienast T, Wrase J, Larsen JL, Braus DF, Smolka MN et al. Net influx of plasma 6-[18 F]fluoro-l-DOPA (FDOPA) to the ventral striatum correlates with prefrontal processing of affective stimuli. Eur J Neurosci 2006; 24: 305-313.
7. Schlagenhauf F, Rapp MA, Huys QJM, Beck A, Wüstenberg T, Deserno L et al. Ventral striatal prediction error signaling is associated with dopamine synthesis capacity and fluid intelligence. Hum Brain Mapp 2013; 34: 1490-1499.
8. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci 1998; 18: 5901-5907.
9. Lotharius J, Brundin P. Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein. Nat Rev Neurosci 2002; 3: 932-942.
10. van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Thérapie 1966; 160: 492-494.
11. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull 2009; 35: 549-562.
12. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988; 242: 715-723.
13. Hietala J, Syvälahti E, Vuorio K, Räkköläinen V, Bergman J, Haaparanta M et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995; 346: 1130.
14. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies. Arch Gen Psychiatry 2012; 69: 776-786.
15. Egerton A, Chaddock CA, Winton-Brown TT, Bloomfield MAP, Bhattacharyya S, Allen P et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol Psychiatry 2013; 74: 106-112.
16. Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A, Valmaggia LR et al. Dopamine synthesis capacity before onset of psychosis: a prospective [18 F]-DOPA PET imaging study. Am J Psychiatry 2011; 168: 1311-1317.
17. Ludolph AG, Kassubek J, Schmeck K, Glaser C, Wunderlich A, Buck AK et al. Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: a 3,4-dihdroxy-6-[18 F]fluorophenyl-l-alanine PET study. Neuroimage 2008; 41: 718-727.
18. Dhawan V, Ma Y, Pillai V, Spetsieris P, Chaly T, Belakhlef A et al. Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. J Nucl Med 2002; 43: 1324-1330.
19. Bloomfield MAP, Morgan CJA, Egerton A, Kapur S, Curran HV, Howes OD. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 2014; 75: 470-478.
20. Kumakura Y, Gjedde A, Caprioli D, Kienast T, Beck A, Plotkin M et al. Increased turnover of dopamine in caudate nucleus of detoxified alcoholic patients. PLoS One 2013; 8: e73903.
21. Salokangas RK, Vilkman H, Ilonen T, Taiminen T, Bergman J, Haaparanta M et al. High levels of dopamine activity in the basal ganglia of cigarette smokers. Am J Psychiatry 2000; 157: 632-634.
22. Langer SZ. Presynaptic regulation of the release of catecholamines. Pharmacol Rev 1980; 32: 337-362.
23. Westerink BHC, de Vries JB. On the mechanism of neuroleptic induced increase in striatal dopamine release: brain dialysis provides direct evidence for mediation by autoreceptors localized on nerve terminals. Neurosci Lett 1989; 99: 197-202.
24. Freeze BS, Kravitz AV, Hammack N, Berke JD, Kreitzer AC. Control of basal ganglia output by direct and indirect pathway projection neurons. J Neurosci 2013; 33: 18531-18539.
25. Shi W-X, Pun C-L, Smith PL, Bunney BS. Endogenous DA-mediated feedback inhibition of DA neurons: involvement of both D1-and D2-like receptors. Synapse 2000; 35: 111-119.
26. Saklayen SS, Mabrouk OS, Pehek EA. Negative feedback regulation of nigrostriatal dopamine release: mediation by striatal D1 receptors. J Pharmacol Exp Ther 2004; 311: 342-348.
27. Santiago M, Westerink BHC. The regulation of dopamine release from nigrostriatal neurons in conscious rats: the role of somatodendritic autoreceptors. Eur J Pharmacol 1991; 204: 79-85.
28. Stibe CMH, Kempster PA, Lees AJ, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988; 331: 403-406.
29. Newman-Tancredi A, Cussac D, Audinot V, Nicolas J-P, Ceuninck FD, Boutin J-A et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and α1/α2-adrenoceptor. J Pharmacol Exp Ther 2002; 303: 805-814.
30. Gainetdinov RR, Sotnikova TD, Grekhova TV, Rayevsky KS. In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol 1996; 308: 261-269.
31. Kehr W, Carlsson A, Lindqvist M. Catecholamine synthesis in rat brain after axotomy: interaction between apomorphine and haloperidol. Naunyn Schmiedebergs Arch Pharmacol 1977; 297: 111-117.
32. Walthers JR, Roth RH. Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors. Naunyn Schmiedebergs Arch Pharmacol 1976; 296: 5-14.
33. White FJ, Wang RY. A10 dopamine neurons: role of autoreceptors in determining firing rate and sensitivity to dopamine agonists. Life Sci 1984; 34: 1161-1170.
34. Di Chiara G, Porceddu ML, Vargiu L, Argiolas A, Gessa GL. Evidence for dopamine receptors mediating sedation in the mouse brain. Nature 1976; 264: 564-567.
35. Torstenson R, Hartvig P, Långström B, Bastami S, Antoni G, Tedroff J. Effect of apomorphine infusion on dopamine synthesis rate relates to dopaminergic tone. Neuropharmacology 1998; 37: 989-995.
36. de La Fuente-Fernández R, Lim AS, Sossi V, Holden JE, Calne DB, Ruth TJ et al. Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition. J Cereb Blood Flow Metab 2001; 21: 1151-1159.
37. Ekesbo A, Rydin E, Torstenson R, Sydow O, Låengström B, Tedroff J. Dopamine autoreceptor function is lost in advanced Parkinson's disease. Neurology 1999; 52: 120-125.
38. Pucak ML, Grace AA. Partial dopamine depletions result in an enhanced sensitivity of residual dopamine neurons to apomorphine. Synapse 1991; 9: 144-155.
39. Lal S, Tesfaye Y, Thavundayil JX, Thompson TR, Kiely ME, Nair NPV et al. Apomorphine: clinical studies on erectile impotence and yawning. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 329-339.
40. First MB. Structured Clinical Interview for the DSM (SCID). In: The Encyclopedia of Clinical Psychology. John Wiley & Sons, 2014. Available at http://onlinelibrary.wiley. com/doi/10.1002/9781118625392.wbecp351/abstract (accessed 19 March 2015).
41. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009; 66: 13.
42. Sawle GV, Burn DJ, Morrish PK, Lammertsma AA, Snow BJ, Luthra S et al. The effect of entacapone (OR-611) on brain [18 F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 1994; 44: 1292-1297.
43. Cumming P, Léger GC, Kuwabara H, Gjedde A. Pharmacokinetics of plasma 6-[18 F]fluoro-L-3,4-dihydroxyphenylalanine ([18 F]Fdopa) in humans. J Cereb Blood Flow Metab 1993; 13: 668-675.
44. Egerton A, Demjaha A, McGuire P, Mehta MA, Howes OD. The test-retest reliability of 18 F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage 2010; 50: 524-531.
45. Zhu M-Y, Juorio AV, Paterson IA, Boulton AA. Regulation of aromatic l-amino acid decarboxylase in rat striatal synaptosomes: effects of dopamine receptor agonists and antagonists. Br J Pharmacol 1994; 112: 23-30.
46. Neef C, van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet 1999; 37: 257-271.
47. Grace AA, Bunney BS. Low doses of apomorphine elicit two opposing influences on dopamine cell electrophysiology. Brain Res 1985; 333: 285-298.
48. Levy MI, Davis BM, Mohs RC, Kendler KS, Mathé AA, Trigos G et al. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses. Arch Gen Psychiatry 1984; 41: 520-524.
49. Bloomfield MAP, Pepper F, Egerton A, Demjaha A, Tomasi G, Mouchlianitis E et al. Dopamine function in cigarette smokers: an [18F]-DOPA PET study. Neuropsychopharmacology 2014; 39: 2397-2404.
50. IBM. Downloading IBM SPSS Statistics 21-United States. 2012. Available at http:// www-01.ibm.com/support/docview.wss?uid = swg24032236 (accessed 3 June 2015).
51. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol 2005; 34: 215-220.
52. Lee IA, Preacher K. Calculation for the test of the difference between two dependent correlations with one variable in common, 2013. Available at http:// quantpsy.org.
53. SAMPLE CDFAS. Correlation coefficients covering the cases (i)'The frequency distribution of the values of the correlation coefficient in samples from an indefinitely large population,' Biometrika, Vol. 10, pp. 507v521, 1915. Here the method of defining the sample by the coordinates of. 1921. Available at http:// www.ssnpstudents.com/wp/wp-content/uploads/2015/02/fisher.pdf4-.pdf (accessed 14 August 2015).
54. Steiger JH. Tests for comparing elements of a correlation matrix. Psychol Bull 1980; 87: 245-251.
55. Teicher MH, Polcari A, Anderson CM, Andersen SL, Lowen SB, Navalta CP. Rate dependency revisited: understanding the effects of methylphenidate in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2003; 13: 41-51.
56. Zhang Z, Andersen AH, Avison MJ, Gerhardt GA, Gash DM. Functional MRI of apomorphine activation of the basal ganglia in awake rhesus monkeys. Brain Res 2000; 852: 290-296.
57. Zhang Z, Andersen A, Grondin R, Barber T, Avison R, Gerhardt G et al. Pharmacological MRI mapping of age-associated changes in basal ganglia circuitry of awake rhesus monkeys. Neuroimage 2001; 14: 1159-1167.
58. Zhang Z, Andersen AH, Ai Y, Loveland A, Hardy PA, Gerhardt GA et al. Assessing nigrostriatal dysfunctions by pharmacological MRI in parkinsonian rhesus macaques. Neuroimage 2006; 33: 636-643.
59. Nguyen TV, Brownell AL, Iris Chen YC, Livni E, Coyle JT, Rosen BR et al. Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse 2000; 36: 57-65.
60. Passamonti L, Salsone M, Toschi N, Cerasa A, Giannelli M, Chiriaco C et al. Dopamine-transporter levels drive striatal responses to apomorphine in Parkinson's disease. Brain Behav 2013; 3: 249-262.
61. Torstenson R, Hartvig P, Långström B, Westerberg G, Tedroff J. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. An Neurol 1997; 41: 334-340.
62. Ma GF, Raivio N, Sabrià J, Ortiz J. Agonist and antagonist effects of aripiprazole on D2-like receptors controlling rat brain dopamine synthesis depend on the dopaminergic tone. Int J Neuropsychopharmacol 2014; 18: pyu046.
63. Ito H, Takano H, Arakawa R, Takahashi H, Kodaka F, Takahata K et al. Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA. PLoS One 2012; 7: e46488.
64. Ito H, Takano H, Takahashi H, Arakawa R, Miyoshi M, Kodaka F et al. Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with l-[β-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission? J Neurosci 2009; 29: 13730-13734.
65. Vernaleken I, Kumakura Y, Buchholz H-G, Siessmeier T, Hilgers R-D, Bartenstein P et al. Baseline [18 F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: a positron emission tomography study in healthy subjects. Neuroimage 2008; 40: 1222-1231.
66. McCulloch J, Kelly PA, Ford I. Effect of apomorphine on the relationship between local cerebral glucose utilization and local cerebral blood flow (with an appendix on its statistical analysis). J Cereb Blood Flow Metab 1982; 2: 487-499.
67. Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 2010; 67: 857-865.
68. Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang S-C. 18 F-FDOPA kinetics in brain tumors. J Nucl Med 2007; 48: 1651-1661.
69. Gründer G, Vernaleken I, Müller MJ, Davids E, Heydari N, Buchholz HG et al. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 2003; 28: 787-794.
70. Zhu MY, Juorio AV, Paterson IA, Boulton AA. Regulation of aromatic L-amino acid decarboxylase in rat striatal synaptosomes: effects of dopamine receptor agonists and antagonists. Br J Pharmacol 1994; 112: 23-30.
71. Rowlett J. Neurochemical and behavioral effects of acute and chronic treatment with apomorphine in rats. Neuropharmacology 1991; 30: 191-197.
72. Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transm (Vienna) 2002; 109: 411-420.
73. Nickolson VJ, van Riezen H, van Delft AM. Response changes after repeated low apomorphine: dopamine autoreceptor desensitization or learning? Psychopharmacology (Berl) 1984; 83: 188-193.
74. Jeziorski M, White FJ. Dopamine agonists at repeated 'autoreceptor-selective' doses: effects upon the sensitivity of A10 dopamine autoreceptors. Synapse 1989; 4: 267-280.
75. Tamminga CA, Schaffer MH, Smith RC, Davis JM. Schizophrenic symptoms improve with apomorphine. Science 1978; 200: 567-568.